PROMETAX PATCH 15 rivastigmine 13.3mg/24 hours transdermal drug delivery system sachet

Active ingredient:

rivastigmine, Quantity: 27 mg

Available from:

Novartis Pharmaceuticals Australia Pty Ltd

INN (International Name):

Rivastigmine

Pharmaceutical form:

Drug delivery system, transdermal

Composition:

Excipient Ingredients: acrylates copolymer; dl-alpha-tocopherol; dimeticone 12500; ethyl acetate; methylated trimethylated silica; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane

Administration route:

Transdermal

Units in package:

7 transdermal drug delivery systems, 30 transdermal drug delivery systems

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

EXELON / PROMETAX is indicated for the treatment of patients with mild, moderate and severe dementia of the Alzheimer's type.

Product summary:

Visual Identification: Circular 15 cm2 transdermal drug delivery system, backing layer (beige), bi-layer adhesive matrix and an oversized rectangular overlapping release liner with dimples. Patch backing is printed with "CNFU" and "Prometax Patch 15 (rivastigmine)"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Licence status A

Authorization date:

2015-04-07